How Much Does BPC-157 Cost? (2026 Price Guide)

BPC-157 has no published price. It is not an FDA-approved medicine, so there is no manufacturer list price, no insurance code and no pharmacy copay to anchor against, and the figures that circulate come from research-chemical catalogs and third-party buying guides that nobody independently verifies. We publish no range of our own, for the same reason: the numbers this page used to carry were transcribed from those guides rather than measured, and they were withdrawn rather than repackaged. What follows is what can actually be established — what drives the number, and how to convert any listing you are looking at into dollars per milligram so two vendors can be compared honestly.

BPC-157 cost at a glance

• Published price: none. BPC-157 is not FDA-approved, so no list price, insurance code or copay exists
• Range we quote: none. The ranges this guide used to carry came from third-party buying guides rather than a survey we ran, and were withdrawn — see the method note on our price-per-mg index
• How to compare: divide the listed price by the milligrams in the vial, then compare vendors on that figure rather than on the sticker
• Monthly cost: depends entirely on the dose and cycle, so there is no standard figure to quote
• Biggest cost driver: third-party purity verification (HPLC, mass spec), not vial size
• FDA status: not approved for human use; placed in Category 2 on the 503A bulk-substances review list in 2023; under Pharmacy Compounding Advisory Committee review July 23–24, 2026

How much does BPC-157 cost in 2026?

There is no answer of the form "BPC-157 costs $X." It has no approved human formulation, so there is no manufacturer list price, no insurance code and no pharmacy copay to anchor against. What exists instead is a set of catalog prices for material sold "for research use only," each set by one seller independently, with nothing obliging any of them to price near another.

We do not publish a range for that market, and it is worth being plain about why. The ranges that used to appear here, and on our price index, were transcribed from third-party buying guides — somebody else's numbers, repeated. Two of them did not survive their own arithmetic when it was finally checked. Republishing them under our name would have asserted a methodology we did not have, so they were withdrawn instead: our price-per-mg index covers prescription pricing only, and its method note sets out what a first-party survey would have to state — sampling frame, collection date, and how many sellers it covers — before any range goes back.

Because the market is unregulated at the consumer level, the spread between two sellers for the same nominal "5 mg of BPC-157" can be large, and the cheaper option is not always the better value once purity and dose accuracy are accounted for. Price alone tells you very little about what is actually in the vial. Consult your healthcare provider before considering any peptide protocol, and see our BPC-157 complete guide for the underlying research context.

What drives the price of BPC-157?

Four factors explain most of the price differences you will see:

1. Purity verification depth. Independent third-party analysis — high-performance liquid chromatography (HPLC) for purity, mass spectrometry to confirm the molecule, and endotoxin/sterility testing — adds real cost, and that cost is largely fixed per batch rather than per vial. A vendor that pays for full testing and publishes a current Certificate of Analysis (COA) carries cost a "skip-the-testing" seller does not.
2. Vial size and per-mg math. A larger vial usually costs more in absolute terms but less per milligram, because a fixed share of the cost — testing, filling, packaging, shipping — does not double when the contents do. Buying by total milligrams, not by sticker price, is how you compare honestly.
3. Synthesis quality and yield. BPC-157 is a 15-amino-acid synthetic peptide; solid-phase peptide synthesis with proper purification costs more than crude product, and that shows up in price.
4. Source type. Research-chemical catalogs, longevity/wellness clinics, and compounding pharmacies price very differently (see the next section).

A price far below everything else you are being quoted most often signals unverified purity, an overstated quantity, or under-filled vials rather than a genuine bargain — though we cannot tell you where that line sits in dollars, because saying so would need the market survey this page does not have. Work each listing out per milligram yourself and run a vendor quality checklist before comparing two of them.

How does BPC-157 pricing differ by source: research vendors vs. clinics vs. compounding pharmacies?

There are three broad channels, and they are not interchangeable:

• Research-chemical vendors sell material labeled for research/laboratory use only — not for human consumption. This is the cheapest per-milligram channel and the one most price guides describe, but it sits entirely outside the medical system, with no prescriber, no pharmacist oversight, and highly variable quality control.
• Longevity/wellness clinics bundle BPC-157 into paid programs that may include consultation, supplies, and follow-up. Headline program pricing is higher than a raw vial because you are paying for services, not just peptide.
• Compounding pharmacies are the only channel tied to a prescription and pharmacist oversight — but their ability to compound BPC-157 is exactly what is in regulatory flux in 2026 (next section). Availability and price here depend on the FDA's pending decisions.

The lowest number you find online is almost always the research-vendor channel, and the cost difference between channels largely reflects the absence (or presence) of medical oversight. A licensed healthcare provider can help you weigh those tradeoffs.

What is the real monthly cost of a BPC-157 protocol?

Monthly cost depends entirely on dose and cycle length, which should be set with a clinician rather than copied from a forum. Research and community discussions commonly cite 250–500 mcg per injection, once or twice daily, for short cycles — not a recommendation here, just the range you will encounter.

Using simple arithmetic on a 10 mg vial:

• At 500 mcg/day, a 10 mg vial provides ~20 days, so a 30-day month needs ~1.5 vials. Multiply the current listed price of the vial you are actually looking at by 1.5 to get the monthly peptide cost. We deliberately do not plug a price into that multiplication for you: the only figure worth using is the one on the listing in front of you, today.
• At 250 mcg/day, the same vial stretches ~40 days, lowering monthly peptide cost accordingly.

These figures cover the peptide only. A realistic budget also includes bacteriostatic water, insulin syringes, alcohol swabs, and sharps disposal, plus — in any responsible scenario — the cost of a consultation and any baseline lab work your provider recommends. Dosing and cycle length should be personalized with a provider; this section is illustrative math, not a protocol. Consult your healthcare provider before starting any peptide protocol.

Why is BPC-157 not just available at a normal pharmacy (and how does that affect price)?

The single biggest reason BPC-157 pricing is so messy is its regulatory status. BPC-157 is not FDA-approved for any use, and in 2023 the FDA placed it in Category 2 of its review of bulk drug substances nominated for compounding under section 503A — substances for which the agency identified potential significant safety risks pending further evaluation, and which were therefore not eligible for the interim compounding policy (U.S. Food and Drug Administration, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks).

In 2026 the picture is shifting. The FDA's Pharmacy Compounding Advisory Committee (PCAC) met on July 23–24, 2026 to discuss BPC-157 (reviewing BPC-157 free base and BPC-157 acetate as separate nominations) along with several other peptides, for possible inclusion on the 503A bulks list (U.S. PCAC voted in favor of BPC-157, but the recommendation is advisory and the bulks list is unchanged — see full regulatory status. FDA, July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee). The FDA removed BPC-157 from the explicit Category 2 prohibition in April 2026 after the underlying nominations were withdrawn, moving it into a transitional, under-review state; the agency's bulk-substances page, updated April 22, 2026, now lists BPC-157 as nominated-but-withdrawn rather than Category 2 (FDA, Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks). But removal from Category 2 is not FDA approval and does not by itself add BPC-157 to the positive bulks list.

Why this matters for price: because no FDA-approved product exists and legitimate pharmacy compounding has been constrained, most consumer-facing supply has flowed through the unregulated research-chemical market, where prices are low but quality and accuracy are unverified. If the July 2026 PCAC review ultimately expands compliant compounding access, the pricing and oversight landscape could change. Legal status varies by jurisdiction; consult a lawyer for binding advice.

Is cheaper BPC-157 worth it? What the research actually shows

It is tempting to chase the lowest price, but the evidence base is the reason quality verification matters more than saving a few dollars. Most BPC-157 research is preclinical (animal and cell-culture) — not large human clinical trials. In a rat Achilles-tendon model combined with cell-culture work, BPC-157 promoted tendon healing through tendon outgrowth, improved cell survival under oxidative stress, and increased fibroblast migration (Chang et al., 2011, Journal of Applied Physiology). Follow-up work reported that BPC-157 up-regulated the growth-hormone receptor in tendon fibroblasts at both mRNA and protein levels, a proposed mechanism for its effect on connective tissue (Chang et al., 2014, Molecules). Review literature describes BPC-157 as stable in human gastric juice with no reported toxicity in early inflammatory-bowel-disease trials of related formulations (Sikiric et al., 2020, Gut and Liver; Sikiric et al., 2006, Current Pharmaceutical Design).

Research in animal models suggests BPC-157 may support tissue repair; robust human efficacy and long-term safety data are limited. That uncertainty is exactly why paying for verified purity — rather than buying the cheapest unverified vial — is the cautious approach. Consult your healthcare provider before starting any peptide protocol.

How can you compare BPC-157 prices fairly?

To avoid overpaying or buying low-quality material:

1. Convert everything to price per milligram. Worked example, with made-up numbers: if one vendor lists a 5 mg vial at $50 and another a 10 mg vial at $85, the second is the cheaper peptide ($8.50/mg against $10/mg) even though its sticker is higher.
2. Demand a current COA. A real, recent third-party COA (HPLC purity + mass-spec identity) is non-negotiable; "tested" with no document is not testing.
3. Reject prices that are too good. Far-below-market pricing usually means a cost was cut somewhere you cannot see.
4. Account for total protocol cost, including supplies and provider consultation — not just the vial.
5. Re-check legal status, which is actively changing in 2026.

For a deeper framework, see our guide to spotting a quality peptide vendor.

Next steps: the rest of our Sourcing library covers the surrounding ground, and our Healing hub groups the guides that share this goal. If you are weighing the two tissue-repair peptides against each other, our BPC-157 vs TB-500 comparison puts them side by side.

Frequently asked questions

Q: How much does a single 5 mg vial of BPC-157 cost in 2026? A: There is no published price to quote, and we do not quote one. BPC-157 has no FDA-approved formulation, so no list price, insurance code or standardized pharmacy price exists; what you find are catalog prices for "research use only" material, set by each seller independently. The ranges this guide used to carry were transcribed from third-party buying guides rather than measured, so they were withdrawn. Take the price on the listing in front of you, divide it by the milligrams in the vial, and compare vendors on that figure — and consult your healthcare provider before considering any protocol.

Q: Why is BPC-157 so cheap compared to prescription medications? A: Most consumer-facing BPC-157 is sold through the unregulated research-chemical channel rather than as an FDA-approved drug, so it carries none of the costs of clinical trials, FDA approval, or pharmacy distribution. That low price reflects a lack of oversight, not a bargain: purity, identity, and fill quantity are frequently unverified. A listing priced far under everything else you are being quoted is widely read as a red flag for unverified purity or overstated quantity, though we publish no dollar threshold, because that would take a market survey we have not run. Verified third-party testing is what you are really paying for.

Q: What is a fair price per milligram for BPC-157? A: There is no authoritative benchmark, and we publish no figure of our own — the per-milligram ranges this guide used to give came from third-party buying guides rather than a survey we ran, and were withdrawn. The useful question is not "what is fair" but "what am I comparing": convert every listing to price per milligram, then judge it against the other listings you have in front of you on the same day. The cost of HPLC and mass-spectrometry testing is largely fixed per batch, so legitimate testing sets a practical floor — which is why a listing far under its peers usually reflects unverified purity, under-filled vials or overstated quantity rather than genuine efficiency.

Q: How much does a full BPC-157 protocol cost per month? A: Monthly cost depends on dose and cycle, which should be set with a provider, not copied online. At a commonly cited 500 mcg/day a 10 mg vial lasts about 20 days, so a month takes roughly 1.5 vials — multiply the current listed vial price by 1.5 to estimate the monthly peptide cost. A 250 mcg/day approach costs about half as much. Add bacteriostatic water, syringes, swabs, sharps disposal, and any consultation or lab fees your clinician recommends for a realistic total. Consult your healthcare provider before starting any peptide protocol.

Q: Is BPC-157 covered by insurance? A: No. BPC-157 is not FDA-approved for any use, so it has no insurance reimbursement, no copay, and no standardized pharmacy price. Any BPC-157 you encounter is sold either as "research use only" material or through cash-pay clinic programs and (where regulations allow) compounding. Because there is no approved product, all costs are out of pocket. This is one reason its pricing is so variable across vendors and channels.

Q: Will the July 2026 FDA advisory committee meeting change BPC-157's price or availability? A: Possibly. The Pharmacy Compounding Advisory Committee discussed BPC-157 on July 23–24, 2026 for potential inclusion on the 503A bulks list (U.S. FDA). If compliant pharmacy compounding access expands, the oversight and pricing landscape could shift toward prescription-based access. However, an advisory-committee discussion is not approval, and any outcome would not make BPC-157 an FDA-approved drug. Legal status varies by jurisdiction; consult a lawyer for binding advice.

Q: Does a higher price mean BPC-157 is more effective? A: Price does not measure efficacy. A higher price may reflect better third-party purity testing, sterility verification, and accurate fill — all of which matter for safety and consistency — but it does not change the underlying evidence. Most BPC-157 research remains preclinical (animal and cell-culture); research in animal models suggests it may support tissue repair, while robust human efficacy data are limited. Pay for verified quality, not for implied benefit, and consult your healthcare provider.

References

1. Chang C-H, Tsai W-C, Lin M-S, Hsu Y-H, Pang J-HS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774–780. https://journals.physiology.org/doi/full/10.1152/japplphysiol.00945.2010
2. Chang C-H, Tsai W-C, Hsu Y-H, Pang J-HS. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066–19077. PMC6271067. https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/ · PubMed: https://pubmed.ncbi.nlm.nih.gov/25415472/
3. Sikiric P, Rucman R, Turkovic B, et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future. Gut and Liver. 2020;14(2):153–167. PMC7096228. https://pmc.ncbi.nlm.nih.gov/articles/PMC7096228/
4. Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Current Pharmaceutical Design. 2006;12(23):2807–2813. PubMed: https://pubmed.ncbi.nlm.nih.gov/17186181/
5. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2, section 503A). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
6. U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
7. U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interim-policy-compounding-using-bulk-drug-substances-under-section-503a-federal-food-drug-and